Anti-Mouse CD80 [Clone 16-10A1] — Purified in vivo PLATINUM™ Functional Grade

Clone 16-10A1 is predominantly used in vivo in mice to block the function of CD80 (B7-1), thereby modulating T cell costimulatory signals essential for immune activation, tolerance, transplant rejection, and cancer immunotherapy.

• Blockade of T Cell Costimulation: 16-10A1 binds to mouse CD80 and inhibits its costimulatory activity, particularly its interaction with CD28 (stimulatory receptor) and CTLA-4 (inhibitory receptor) on T cells, which is vital for regulating T cell activation, proliferation, and cytokine release.

• Immune Tolerance Induction: By blocking CD80-mediated costimulation, the antibody is used experimentally to induce or assess immune tolerance, for instance in autoimmunity or transplantation models.

• Transplant Rejection Studies: 16-10A1 is administered to block CD80 and study its impact on the rejection or acceptance of organ and tissue transplants in mouse models.

• Cancer Immunotherapy Research: The antibody is sometimes used to investigate the role of CD80 in anti-tumor immune responses, and its blockade can help clarify mechanisms of immune evasion or enhance immunotherapeutic strategies.

Other notable in vivo uses include:

• Modulating immune responses: In models of infection or inflammatory disease, especially where precise regulation of T cell activation is important.
• Combinatorial studies: Frequently paired with antibodies targeting other costimulatory molecules such as CD86 to delineate their individual roles in immune regulation.

Key application details:

• Clone 16-10A1 is typically supplied in an unconjugated, low-endotoxin format for systemic administration in mice.
• The antibody is specific for mouse CD80 and does not cross-react with CD86, enabling precise mechanistic studies.
• CD80 is expressed on activated B cells, dendritic cells, macrophages, and T cells in mice.

Summary Table: Common In Vivo Applications of Clone 16-10A1

Caveats:

• 16-10A1 is not used to block CD86 and therefore allows selective investigation of CD80-dependent pathways.
• Optimal dosing and administration protocols are determined empirically for each model and experimental setup.

Alternative meanings:
If you were interested in non-in vivo (e.g., flow cytometry, ELISA) uses, clone 16-10A1 is also widely used for detecting CD80 expression on immune cells in vitro. However, the primary in vivo role is as a blocking antibody.

Commonly used antibodies and proteins with 16-10A1 (anti-mouse CD80) in the literature include:

• Anti-CD86 (B7-2) antibodies: CD86 is the second major co-stimulatory ligand for CD28 and CTLA-4, making it the single most frequent companion used in studies with 16-10A1 to assess co-stimulatory pathways in T cell activation.
• Anti-CD28: CD28 is the receptor for CD80 and CD86 on T cells, so detection or blocking of CD28 is often paired with CD80 detection to dissect costimulatory signaling.
• Anti-CTLA-4 (CD152): As an inhibitory receptor for both CD80 and CD86, CTLA-4 is commonly studied in conjunction with these ligands to examine negative regulation of T cell responses.
• Anti-CD40/CD40L: These proteins are often included when general antigen-presenting cell (APC) or T cell activation is analyzed.
• Anti-CD3 and anti-CD4/CD8: Markers for T cells (CD3), helper T cells (CD4), or cytotoxic T cells (CD8) are frequently used to gate on T cell populations during flow cytometric analysis involving co-stimulation assays.
• Activation markers: Such as CD69, CD25, or Ki67, which are frequently co-stained in immunophenotyping to determine activation or proliferation status during functional studies with 16-10A1.

Summary Table: Common Antibodies/Proteins Used with 16-10A1

In murine immunology literature, when 16-10A1 is used for blocking, phenotyping, or functional assays, anti-CD86 (GL-1 clone) is nearly always included in the same panel so researchers can distinguish or compare the roles of these closely related co-stimulatory ligands. When studying T cell activation pathways, antibodies targeting T cell receptors or activation markers are standard additions.

These combinations allow researchers to parse the complex interplay of costimulation and inhibition in T cell responses, particularly in studies of immune checkpoints or APC–T cell interactions.

Clone 16-10A1 is a widely cited antibody in immunological research due to its specificity for mouse CD80 (B7-1) and its ability to block CD80’s costimulatory function, making it a crucial tool for studying immune modulation, T cell costimulation, and related disease models.

Key findings from scientific literature citations of clone 16-10A1 include:

• Specificity and Mechanism: 16-10A1 binds specifically to mouse CD80 and blocks its interaction with the ligands CD28 (which promotes T cell activation) and CTLA-4 (which inhibits T cells), thereby regulating T cell responses.
• Functional Use: It blocks CD80-dependent costimulatory activity without affecting CD86 function, making it valuable for dissecting CD80- versus CD86-mediated pathways in immune regulation.
• Experimental Applications: Frequently used in studies of T cell costimulation, immune tolerance, transplant models, and cancer immunotherapy, often in combination with antibodies targeting related pathways.
• Cellular Targets: Recognizes CD80 expressed on activated B cells, T cells, dendritic cells, and macrophages.
• Disease Models: Utilized in experiments on autoimmunity, tumor immunity, and regulatory T cell expansion; for example, its use has clarified CD80’s role in local regulatory T cell expansion upon injury.
• Methodological Notes: The antibody is commonly applied in flow cytometry and in vivo blocking assays, with careful titration recommended for optimal performance.

In summary, clone 16-10A1 is recognized for its robust blockade of mouse CD80-mediated costimulation, enabling precise investigation of immune mechanisms in both basic and translational research.

Dosing regimens of clone 16-10A1 (anti-mouse CD80) in mouse models most commonly involve intraperitoneal or intravenous injection at doses around 250 μg per mouse every 3 days, notably for post-bone marrow transplant GVHD models.

Key context and variability:

• In an established protocol for acute graft-versus-host disease (GVHD) models, 250 μg of 16-10A1 was injected intravenously every 3 days after bone marrow transplantation.
• Other published descriptions and product protocols do not specify unique dosing regimens for distinct mouse models, but highlight that 250 μg per dose every 2–3 days is typical for functional in vivo use.
• Detailed, model-specific dose modifications are rarely published; instead, the 16-10A1 dosing mirrors that of many in vivo checkpoint/blockade antibodies in mice, which usually range from 100–250 μg per dose, 2–3 times per week, depending on the specific immune modulation required in the disease model (such as tumor, infection, or transplant settings).
• For in vitro assays (e.g., flow cytometry), considerably lower doses are used (≤0.06 μg/test), but this is not relevant for in vivo systemic dosing.

Summary Table: Typical in vivo dosing for 16-10A1 in mouse models

Important notes:

• Product suppliers and antibody guides affirm that dosing should be titrated for each specific model, especially for combination therapies or models involving altered immune status.
• Some mouse models or experimental endpoints (such as tumor vs. transplant vs. autoimmunity) may require slight adjustments, but published examples consistently use the 250 μg/dose every 2–3 days regimen as a starting point.
• No evidence was found in this search of lower or higher dosing regimens for 16-10A1 in non-GVHD models, but protocols for similar checkpoint or depletion antibodies (anti-CD4, anti-CD8) use overlapping doses and schedules.

In sum, 250 μg every 2–3 days is the standard in vivo starting regimen for clone 16-10A1, with adjustments made empirically depending on the specific experimental mouse model.